| Execution period | Valid until 29/05/2031 |
|---|
NSE filing, NSE: PRIMECAB. Summary written from the filing by ALFA Finder's alert engine.
Prime Cable Industries Ltd: key numbers
- Share price
- ₹190.00
- Market cap
- ₹348.2 Cr
- Revenue (annual)
- ₹234.9 Cr
- Net profit (annual)
- ₹12.24 Cr
- P/E (TTM)
- 28.4×Sector 42.1×
- Promoter holding
- 68.47%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Prime Cable Industries Ltd
All →Prime Cable Industries Other Announcement
Prime Cable Industries replaced its NSE Emerge market maker, appointing NDA Securities effective 14 Oct 2026. Alacrity Securities' resignation takes effect 13 Oct 2026.
Prime Cable Industries Business Update
Prime Cable Industries Limited has appointed NDA Securities Limited as its new Market Maker for equity shares on NSE Emerge, replacing Alacrity Securities Limited.
Prime Cable Industries Annual General Meeting
Prime Cable Industries Limited conducted its 18th Annual General Meeting on September 30, 2026. Shareholders approved financial statements and increases in managerial remuneration for the company's directors.
Prime Cable Industries Bags ₹16.49 Cr Order from A reputed Indian listed company
Prime Cable Industries Limited received a ₹16.49 Crore order for 11 KV MV cables from a reputed listed company. The contract execution period is 4 months.
- Value
- ₹16.49 Cr
- From
- A reputed Indian listed company
- Execution
- 4 Months
Prime Cable Industries Other Announcement
Prime Cable Industries Limited has received a renewed NABL Accreditation for its Quality Assurance Laboratory, valid until August 2030, with an expanded scope for cable testing.
Prime Cable Industries Annual Report
Prime Cable Industries filed its 18th Annual Report for FY2025-26 along with the AGM notice. No fresh transaction or monetary value is disclosed.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.